Table1: Clinical and biochemical parameters of the PA-patients with PRKACA somatic mutations.
Somatic PRKACA mutations were identified by exome sequencing in 2/122 (1.6%) cases described in Table 1 . Case 1 presented a c.262C>G (p.His88Asp) mutation in exon 4 while a c.617A>C (p.Leu206Arg) mutation in exon 7 was identified in case 2 (Fig.1A) . His88 is the only residue in the small lobe of the conserved catalytic core of the C subunit of PKA to interact with the phosphate on residue Thr198, the essential phosphorylation site on the surface of the large lobe (Fig.1B) . Situated at the cleft interface, His88 was found to complement Ser100 at the auto-inhibitor sequence P+2 in the type I regulatory subunit and therefore His88 is also involved in the interaction with the RIα subunit of PKA. Measurement of PKA catalytic activity demonstrated that mutated His88Asp Cα subunit of PKA resulted in a significantly lower enzymatic PKA activity in comparison to the wild-type enzyme when co-transfected with either RIα or with RIIβ in HEK293 cells, both in presence and in absence of cAMP (Fig.1C) . On the contrary, mutated Leu206Arg resulted in a constitutive elevated activity not suppressed by any of the regulatory subunits, as previously described (6). The APA resected from the two cases were of similar size (0.9 vs 1.2 cm) and both were composed of zona fasciculata and zona glomerulosa-like cells. Double immunofluorescence analysis ( Fig. 2A) showed CYP11B2 expression and, to a lesser extent, CYP11B1 in case 1; conversely, the adenoma cells in case 2 were mostly positive for CYP11B1. Multi-steroid analysis of peripheral plasma from case 2 found hybrid serum steroids 18-oxocortisol and 18-hydroxycortisol to be elevated as observed with the multi-steroid fingerprint of patients carrying KCNJ5 somatic mutations (Fig.2B ).
Panel A shows two paired sequence chromatograms of tumor and peripheral blood from case 1 and case 2. In case 1 (left) a somatic variant in PRKACA (c.262C→G) was identified in the aldosterone-producing adenoma, resulting in a His88Asp substitution. In case 2 (right) a somatic mutation in PRKACA (c.617A→C) was found, resulting in a Leu206Arg substitution.
Panel B shows the location of His88 within the tridimensional structure of the Cα subunit of PKA. This residue, together with Arg166 and Lys 190, binds and stabilizes phospho-Thr198 (left). Conversely, the substitution Asp88 (right, in red) disrupt this interaction.
Panel C shows the functional characterization of PRKACA mutations. Enzymatic PKA activity was quantified on lysates of human embryonic kidney 293 cells co-expressing Cα (mutant or non-mutant) and RIα (left) or RIIβ (right) in a molar ratio of R:C equal to 1:8. Activity was measured in presence or absence of cyclic AMP (cAMP) using a specific peptide substrate and measured by a fluorescent, in-gel migration assay. The His88Asp variant exhibits a lack of response to cAMP stimulation while the Leu206Arg mutant is constitutively active. "*" indicates P<0.05 for the comparison with the wild-type PKA activity in absence of cAMP; "#" indicates P<0.05 for the comparison with the wild-type PKA activity in presence of cAMP. Representative input blots are shown below the graphs. Panel B shows the 2D-canonical plot derived from discriminant analysis for plasma concentrations of seven adrenal steroids (aldosterone, 18-oxocortisol, 18-hydroxycortisol, corticosterone, 11-deoxycorticosterone, 21-deoxycortisol and cortisol) used for 79 aldosterone-producing adenomas APAs with and without (wild-type, grey) somatic mutations of KCNJ5 (blue), CACNA1D (green) and ATP1A1 or ATP2B3 (red) genes. The crosses represent the centroids for each group. The empty and bold circles indicate the location within canonical plots of the two adenomas with the PRKACA somatic variant p.His88Asp (case 1) and the PRKACA somatic mutation p.Leu206Arg (case 2) respectively.
